Risky Business: The FDA And Drug Development For The Fatally Ill

Mar 6 2014, 12:01am CST | by

Risky Business: The FDA And Drug Development For The Fatally Ill
Photo Credit: Forbes Business

If you’ve ever waited for treatment in the ER—for yourself or perhaps for a child suffering a broken bone or an asthma attack—then you’re familiar with how agonizing it can be, knowing that the answer might be just on the other side of the swinging doors. For parents of seriously ill children, this kind of waiting can last for years. And when treatment options are still stuck in the development, testing, or approval processes, the wait can cost patients their lives.

The FDA has set up these processes for good reason; they protect the public from experiencing severe, unexpected side effects due to unsafe drugs, which could actually make people even sicker than they already were. But for seriously ill patients, sometimes the risk is worth taking if there’s any chance of increasing their survival rates. In these cases, the burdensome approval process to get drugs on the market—which can take up to 18 years—is detrimental both to pharmaceutical companies and to patients. The recent controversy over the FDA’s refusal to approve eteplirsen, a drug intended to treat Duchenne muscular dystrophy, is a prime example of this. Eteplirsen has shown some promising results in clinical trials, but the data still isn’t satisfactory enough for FDA approval, since it has a hard time assessing benefit and risk across a spectrum of perspectives and experiences. Patients and their families beg for access to the drug, to no avail.

Unlike other industries, pharmaceutical companies are also legally restricted from directly marketing to consumers or including them in the prototyping phase of the design process. This can prevent consumers from providing vital feedback that could shape drug effectiveness, as well as from learning about experimental options when they are available. With most conditions, the risks of experimentation would be too high. But if you had a fatal disease and were told you only had one year to live, wouldn’t you prefer to be allowed to make your own choice?

Sharon Terry, an Ashoka Fellow, and Genetic Alliance have developed a platform that facilitates the responsible engagement of the FDA with patients such as these, and they’re getting patients directly involved in voicing their concerns about the current system. The FDA’s initiative is called Patient-Focused Drug Development (PFDD), and it is designed to assess risks and benefits for specific patient communities.  Genetic Alliance is crowdsourcing input for the FDA to hear from patients.  Terry hopes to increase the available pool of information—information about patients’ genetics and other personal data—to help accelerate discovery. She’d like to see a systemic solution across all diseases, rather than solutions that work on a case by case basis.  To do that, she and her partners are putting in place a structure to empower disease groups and patients to vocalize their needs to the FDA and determine how and with whom their data is shared. Currently Genetic Alliance works with eight disease groups on PFDD and has enabled patients from each community to serve as guides with the goal of getting input from patient communities. It hopes to expand its work to more diseases in the next few years, and eventually to every disease.

Terry’s initiative has recently been awarded a $1 million contract from the Patient Centered Outcomes Research Institute to be a part of the National Patient Centered Clinical Research Network. This news could mean big things ahead for patients with genetic diseases.

If their work is successful, the FDA will begin to distinguish between the process for approving standard use drugs and the process for approving drugs that are designed to treat or cure severe disease. With increased collaboration between pharmaceutical companies and patients with a high risk tolerance, the FDA can gain data to stand on, which could help speed up drug patent approval. Patients would also be able to participate in drug design, thus improving the development process.

By challenging some of the obstacles that prevent access to potentially life-saving medicine, it may be possible to empower families to stop waiting and start acting. Risky? Maybe. But thousands of families risk even more every day.

This post is part of a series of essays on the power and potential of feedback loops to dramatically increase social impact (see the first one here). This work is being catalyzed by Feedback Labs with support from the Rita Allen Foundation.

Come join us here.

Source: Forbes Business

 
 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

Finnish scientists identify new type of black hole
Helsinki, Oct 31 (IANS) Finnish researchers have discovered a new type of low-mass black hole, which is a bright celestial body that emits X-ray, the University of Turku has said.
 
 
Union Carbide ex-chief Warren Anderson is dead
Washington, Oct 31 (IANS) Warren Anderson, former chief executive officer of the Union Carbide Corporation, is dead, a media report said Friday. He was 92.
 
 
Himalayan Viagra fuels gold rush for local Tibetans
Washington, Oct 31 (IANS) Overwhelmed by people trying to find the prized medicinal fungus known as Himalayan Viagra, two isolated Tibetan communities have managed to implement a successful system for the sustainable harvest of the precious natural resource, suggests research.
 
 
Oceans were always there on Earth: Scientists
Washington, Oct 31 (IANS) Debunking previous theories that water came late to Earth well after the planet had formed, researchers have significantly moved back the clock for the first evidence of water on Earth and in the inner solar system.
 
 
 

Latest from the Network

Orson Welles last film to be released
Orson Welles' final movie will finally be released next year. The acclaimed filmmaker had worked on 'The Other Side of the Wind' - which chronicles a temperamental film director battling with the Hollywood establishment...
Read more on Movie Balla
 
Game of Thrones stars get pay rise
'Games of Thrones' cast members will be paid $300,000 an episode. Five of the shows biggest stars - Peter Dinklage, Kit Harington, Lena Headey, Emilia Clarke and Nikolaj Coster-Waldau - have landed bumper payrises after...
Read more on Celebrity Balla
 
Mike Tyson: I was abused
Mike Tyson claims he was sexually abused as a child. The 48-year-old retired boxer was ''snatched'' off the street when he was seven by an ''old man'', who he never saw again after the shocking one-time incident....
Read more on Celebrity Balla
 
Amanda Bynes released from psychiatric facility
Amanda Bynes has been released from a psychiatric treatment facility. The 'Easy A' actress was spotted walking around Sunset Strip, West Hollywood, last night (30.10.14), 19 days after she was admitted to the hospital...
Read more on Celebrity Balla
 
Lindsay Lohan sued for 60m
Lindsay Lohan is being sued for over $60 million. A website developer has filed a case against the 'Mean Girls' actress and her brother Michael in which he accused them of stealing one of his ideas. According to Fima...
Read more on Celebrity Balla
 
Russell Brand to give money away
Russell Brand plans to give away his future earnings. The 39-year-old star insists he ''doesn't need'' to make money for himself anymore so wants to use his fortune to help those in need. He told Vanity Fair magazine...
Read more on Celebrity Balla
 
Koji Uerhara Signs 2-Year, $18M Deal With Boston Red Sox
Ace Japanese closer Koji Uehara signed a two-year deal with the Boston Red Sox on Oct. 30.According to MLB.com's Ian Browne, Uehara's deal is worth $18 million:"Perhaps it was fitting that the Red Sox announced a two-...
Read more on Sport Balla
 
Finnish scientists identify new type of black hole
Helsinki, Oct 31 (IANS) Finnish researchers have discovered a new type of low-mass black hole, which is a bright celestial body that emits X-ray, the University of Turku has said. Researchers at the Finnish university...
Read more on Business Balla
 
Union Carbide ex-chief Warren Anderson is dead
Washington, Oct 31 (IANS) Warren Anderson, former chief executive officer of the Union Carbide Corporation, is dead, a media report said Friday. He was 92. His death revived memories of the 1984 Bhopal gas tragedy. He...
Read more on Business Balla
 
Himalayan Viagra fuels gold rush for local Tibetans
Washington, Oct 31 (IANS) Overwhelmed by people trying to find the prized medicinal fungus known as Himalayan Viagra, two isolated Tibetan communities have managed to implement a successful system for the sustainable...
Read more on Business Balla